AngioJet rheolytic thrombectomy under superior vena cava filter protection for acute upper extremity deep vein thrombosis in patients with cancer: a single-center, retrospective analysis
- 1Department of Vascular Surgery, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, People's Republic of China
- 2Department of Geriatrics, Qingdao Central Hospital, University of Health and Rehabilitation Sciences, Qingdao, People's Republic of China
Abstract
Objective
The incidence of upper extremity deep vein thrombosis (UEDVT) is increasing, and percutaneous mechanical thrombectomy (PMT) is receiving more attention as a treatment option. This study aims to evaluate the efficacy and clinical outcomes of PMT combined with superior vena cava (SVC) filter protection in cancer patients with acute UEDVT.Methods
This study included all patients with acute UEDVT who underwent treatment with an 8-Fr AngioJet thrombectomy system (Boston Scientific) under the protection of a retrievable SVC filter between January 1, 2020, and October 1, 2025. The evaluation indicators included technical success rate (defined as a thrombus clearance rate >80%), intraoperative adverse events, degree of limb swelling relief, incidence of pulmonary embolism, and thrombus recurrence during follow-up.Results
A total of 19 patients (10 female; mean age 60.84 ± 11.30 years) were included. All patients had secondary UEDVT and a history of malignant tumors, with 14 cases (73.7%) having a history of central venous catheterization. All procedures achieved technical success, with no severe adverse events such as major bleeding occurring intraoperatively, nor were there any new symptomatic pulmonary embolisms. The average circumference of the affected limb 10 cm above the elbow before surgery was 29.83 ± 2.20 cm, which decreased to 26.98 ± 2.0 cm on the second postoperative day. During the 6-month follow-up, one patient with advanced lung cancer developed swelling of the upper limb on postoperative day 136, confirmed by ultrasound to be a recurrence of deep vein thrombosis; another patient was found to have an asymptomatic mural thrombus on ultrasound examination on postoperative day 28.Conclusion
PMT with the 8-Fr AngioJet system and SVC filter protection appears to be a safe and effective treatment option for cancer patients with acute UEDVT.
Related
- Lower-extremity Deep Vein Thrombosis after Plastic Surgery: Clinical Characteristics and Outcomes in a Retrospective Case Series
- Anatomical distribution of lower-extremity deep vein thrombosis and pulmonary embolism: a retrospective study with finite-element analysis of calf muscle-vein mechanics
- CO012 | LONG-TERM RISK OF RECURRENT VENOUS THROMBOEMBOLISM IN ADULT PATIENTS WITH ACTIVE CANCER AND FIRST CATHETER-RELATED UPPER EXTREMITY DEEP VEIN THROMBOSIS AFTER DISCONTINUATION OF ANTICOAGULANT TREATMENTS AND LINE REMOVAL: A RETROSPECTIVE MULTI-CENTER COHORT STUDY – CANCER-CRT STUDY
- Development and internal validation of a nomogram for estimating concurrent superficial vein thrombosis at presentation in patients with lower extremity varicose veins
- Mechanical thrombectomy for superior sagittal sinus thrombosis in early pregnancy: a case report
BibTeX
@article{zhai2026angiojet,
title = {{AngioJet rheolytic thrombectomy under superior vena cava filter protection for acute upper extremity deep vein thrombosis in patients with cancer: a single-center, retrospective analysis}},
author = {Shaobo Zhai and Jia Yu and Jifeng Sun and Yangyang Yu and Cheng Gao},
journal = {Research and practice in thrombosis and haemostasis},
year = {2026},
month = oct,
doi = {10.1016/j.rpth.2026.107002},
url = {https://europepmc.org/article/PMC/PMC13717018},
note = {CC BY},
}
RIS
TY - JOUR
TI - AngioJet rheolytic thrombectomy under superior vena cava filter protection for acute upper extremity deep vein thrombosis in patients with cancer: a single-center, retrospective analysis
AU - Shaobo Zhai
AU - Jia Yu
AU - Jifeng Sun
AU - Yangyang Yu
AU - Cheng Gao
PY - 2026
DA - 2026/10/01
JO - Research and practice in thrombosis and haemostasis
DO - 10.1016/j.rpth.2026.107002
UR - https://europepmc.org/article/PMC/PMC13717018
AB - Objective The incidence of upper extremity deep vein thrombosis (UEDVT) is increasing, and percutaneous mechanical thrombectomy (PMT) is receiving more attention as a treatment option. This study aims to evaluate the efficacy and clinical outcomes of PMT combined with superior vena cava (SVC) filter protection in cancer patients with acute UEDVT.Methods This study included all patients with acute UEDVT who underwent treatment with an 8-Fr AngioJet thrombectomy system (Boston Scientific) under the protection of a retrievable SVC filter between January 1, 2020, and October 1, 2025. The evaluation indicators included technical success rate (defined as a thrombus clearance rate >80%), intraoperative adverse events, degree of limb swelling relief, incidence of pulmonary embolism, and thrombus recurrence during follow-up.Results A total of 19 patients (10 female; mean age 60.84 ± 11.30 years) were included. All patients had secondary UEDVT and a history of malignant tumors, with 14 cases (73.7%) having a history of central venous catheterization. All procedures achieved technical success, with no severe adverse events such as major bleeding occurring intraoperatively, nor were there any new symptomatic pulmonary embolisms. The average circumference of the affected limb 10 cm above the elbow before surgery was 29.83 ± 2.20 cm, which decreased to 26.98 ± 2.0 cm on the second postoperative day. During the 6-month follow-up, one patient with advanced lung cancer developed swelling of the upper limb on postoperative day 136, confirmed by ultrasound to be a recurrence of deep vein thrombosis; another patient was found to have an asymptomatic mural thrombus on ultrasound examination on postoperative day 28.Conclusion PMT with the 8-Fr AngioJet system and SVC filter protection appears to be a safe and effective treatment option for cancer patients with acute UEDVT.
SN - 2475-0379
ER -